Development of specific Rho-kinase inhibitors and their clinical application. - Wikidata - awgldk - TriplyDB

Development of specific Rho-kinase inhibitors and their clinical application.

Development of specific Rho-kinase inhibitors and their clinical application.

http://www.wikidata.org/entity/Q36280685

about

An emerging treatment option for glaucoma: Rho kinase inhibitors Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy Local, persistent activation of Rho GTPases during plasticity of single dendritic spines Metabolic actions of Rho-kinase in periphery and brain Rho kinase as a target for cerebral vascular disorders Corticotropin releasing factor-induced CREB activation in striatal neurons occurs via a novel Gβγ signaling pathway Phos-tag-based analysis of myosin regulatory light chain phosphorylation in human uterine myocytes A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor Proliferation of mouse embryonic stem cell progeny and the spontaneous contractile activity of cardiomyocytes are affected by microtopography Nephrons require Rho-kinase for proximal-distal polarity development Targeting protein kinases in central nervous system disorders The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.Remodeling of actin cytoskeleton in mouse periosteal cells under mechanical loading induces periosteal cell proliferation during bone formation.Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.Tolerance of neurite outgrowth to Rho kinase inhibitors decreased by cyclooxygenase-2 inhibitor.Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.Molecular characterization of the effects of Y-27632.A photoactivatable small-molecule inhibitor for light-controlled spatiotemporal regulation of Rho kinase in live embryos.Phasic contractions of isolated human myometrium are associated with Rho-kinase (ROCK)-dependent phosphorylation of myosin phosphatase-targeting subunit (MYPT1).Constriction of retinal arterioles to endothelin-1: requisite role of rho kinase independent of protein kinase C and L-type calcium channels Novel mechanism for negatively regulating Rho-kinase (ROCK) signaling through Coronin1B protein in neuregulin 1 (NRG-1)-induced tumor cell motility.Abrogation of airway hyperresponsiveness but not inflammation by rho kinase insufficiency.Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells.The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma.Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface.Myosin-II-mediated cell shape changes and cell intercalation contribute to primitive streak formation.Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork.Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.Calcium-independent phospholipase A2 participates in KCl-induced calcium sensitization of vascular smooth muscle.Rho-kinase mediated cytoskeletal stiffness in skinned smooth muscle.Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.Novel ocular antihypertensive compounds in clinical trials.Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.The influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone.

P2860

Q22305851-559C23CC-130B-4820-8150-C657D5E842BB Q24611233-22022B1D-48B3-4257-846E-B8A951E1289D Q24629206-32CF9BF3-52E9-4855-B8EC-737D4A6B2BA4 Q26864028-2A99A070-2FCE-464A-AD9E-A36A68B6B8D9 Q28081507-460CA703-DE61-43B4-8B9A-0654777D6F7E Q28477480-9313EF2E-A980-4FA1-AB3B-D09CEBFB02C1 Q28478511-88809027-9E49-4556-AAD8-BFD077EBE93E Q28828478-9A56B5BD-733B-4D3A-A66A-328D8143E03D Q30541635-5591C7AF-CF12-4594-8B00-8797AC363D81 Q30544951-803C6386-FDFE-4004-955F-E135840658D5 Q33671660-658E42D6-145F-43A5-AC67-35413AFA612E Q33756580-F2EA76F4-FE85-429E-8816-02952DB541FC Q34026335-96653B44-40A6-44E1-A916-9C77175291D8 Q34325540-5C8D6B3C-F48F-45F8-AB46-0112BEBA1290 Q34358302-9F5C625B-A45A-4675-B795-BA0BE1243CBF Q34402810-EF5A91A3-12BE-4330-8917-58C76542BD79 Q34569957-F366CB46-135B-4D50-A2D1-1DC5E3E85F76 Q35624859-F5FD1278-04F9-41E1-A437-286BE5A57781 Q35920703-84674AA6-B64C-4694-96EF-D98324B3D6C1 Q36035002-81F14BB6-61A4-4A50-A3A3-1C55DB20AB32 Q36052415-9AFA029C-2381-447C-9724-C2D3107CD7F8 Q36057251-3DA6FE79-208D-4E73-A419-7C4476345577 Q36171342-9FE9B89E-9E83-4DC1-BB8C-156FC709D53B Q36499750-09D0EBAB-527D-46C5-965C-CBB3072D3483 Q36818193-DB778C94-4AD0-468E-9561-C24A788E26A9 Q36828033-F318C059-3794-4102-A0A4-03A7624D5CA8 Q36887547-730E9D43-9515-4D1E-BE97-197AC7731A4D Q36951037-B7522C8E-73E8-4E69-AC70-4F8CD532CB6D Q36964914-77CCCCCA-F953-44E0-A28C-406170345C98 Q36977724-23279DD8-C997-4BC5-B070-8959277F5ED6 Q37139305-A5AA5511-5A36-42F2-ABD3-15D26B260677 Q37245152-D2F6B1E8-D084-444F-B7E8-B0CFD9713C3F Q37346119-0982C39B-F242-4AB5-87BE-D0F74AF96845 Q37486257-4051CAD2-E333-46DC-92EA-9E0D66CE463E Q37769931-C94BBD4B-E4DC-420D-AC81-0CB6F585F34F Q37883078-B0EB5AEB-0B04-476A-A4EA-330328ED7B57 Q38086608-20E3A40B-7EC0-47DF-B135-502BBFA36CD5 Q38149325-5EA5D245-9D91-41B6-A7C2-E7FD1A9FCEE5 Q38584194-C7C1723D-C261-4B16-9080-0F20699C8BA5 Q38662676-23510E7B-EF3F-46D3-8378-D2EB033244DF

P2860

Development of specific Rho-kinase inhibitors and their clinical application.

http://www.wikidata.org/entity/Q36280685

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Development of specific Rho-kinase inhibitors and their clinical application.

@ast

Development of specific Rho-kinase inhibitors and their clinical application.

@en

type

label

Development of specific Rho-kinase inhibitors and their clinical application.

@ast

Development of specific Rho-kinase inhibitors and their clinical application.

@en

prefLabel

Development of specific Rho-kinase inhibitors and their clinical application.

@ast

Development of specific Rho-kinase inhibitors and their clinical application.

@en

P1433

Q36280685-1FC3AAD7-2969-4FB8-9788-C1EFAA4301D7

P1476

Q36280685-3C4C628A-7EE0-49D4-B4DF-C22056025267

P2093

Q36280685-09C1D2F6-8E07-43DC-8F9C-58B034E8E674

Q36280685-2A0836D9-EA80-4014-8A3D-F8E429BF58C2

Q36280685-2FDC0C62-0088-4603-BA85-B7999B6B1780

Q36280685-368D7CFF-80F8-44DF-9853-7224B0364FF1

Q36280685-7C7FAF9B-9C2C-4DD4-8897-6185A12BE14C

Q36280685-8B0F09B6-F33F-46D1-B142-A0B489912F24

Q36280685-A013B804-7B4E-4466-A961-65662D683A1A

Q36280685-A8B03B6E-7E11-4D10-9058-A72F52292222

Q36280685-BB07F1CA-4184-4C09-83C5-19E50AC0AA8F

P304

Q36280685-DE519801-6267-404B-914F-A6CD30730F17

P31

Q36280685-A4911D8D-C67E-43FD-98EF-912C57AE54DA

P356

Q36280685-C0DD3B48-7EE4-46A6-B451-107CB45FC401

P407

Q36280685-01730DCB-28FA-4E33-9C41-150FE7431A43

P433

Q36280685-8EB76238-8118-4CD0-8D56-B73AD0B0584B

P478

Q36280685-3D299B6F-5A48-4F8C-9AFA-07405A54CCD5

P577

Q36280685-58D2746C-127F-46B1-977B-412D9525FE65

P698

Q36280685-31FC1200-E5C1-4353-BA12-6C0121256224

P356

J.BBAPAP.2005.06.015

P1433

Biochimica et Biophysica Acta

P1476

Development of specific Rho-kinase inhibitors and their clinical application.

@en

P2093

Hajime Yamada

http://www.w3.org/2001/XMLSchema#string

Hideo Yoshizaki

http://www.w3.org/2001/XMLSchema#string

Hiromichi Shigyo

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nakao

http://www.w3.org/2001/XMLSchema#string

Hiroyoshi Hidaka

http://www.w3.org/2001/XMLSchema#string

Junko Totsuka

http://www.w3.org/2001/XMLSchema#string

Masahiro Tamura

http://www.w3.org/2001/XMLSchema#string

Masami Shiratsuchi

http://www.w3.org/2001/XMLSchema#string

Takatoshi Ozawa

http://www.w3.org/2001/XMLSchema#string

P304

245-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBAPAP.2005.06.015

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

1754

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16213195

http://www.w3.org/2001/XMLSchema#string